Physician profile
Arthur Caire
NPI 1346474913
$2,873.42
in general payments reported to CMS, 2019-2025
38 companies · $779 in 2025
The $779 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $134 · 2021: $503 · 2022: $103 · 2023: $283 · 2024: $449 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,510.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $549.05 | 2021-2025 | Barrigel, Urolift |
| Astellas Pharma US INC | $356.84 | 2019-2024 | Xtandi, Myrbetriq |
| Sumitomo Pharma America, INC. | $190.58 | 2024-2025 | Orgovyx |
| Dendreon Pharmaceuticals LLC | $186.24 | 2022-2025 | Provenge |
| Pfizer INC. | $161.43 | 2019-2025 | |
| Agiliti Surgical, INC. | $139.39 | 2023 | Soltive |
| Urogen Pharma, INC. | $102.20 | 2022-2025 | |
| Amgen INC. | $84.04 | 2019 | |
| Ferring Pharmaceuticals INC. | $82.88 | 2024-2025 | Adstiladrin |
| Calyxo, INC. | $75.82 | 2025 | Cvac Aspiration System |
| Bayer Healthcare Pharmaceuticals INC. | $74.15 | 2021-2025 | |
| Boston Scientific Corporation | $69.93 | 2019-2024 | Moses 550 Dfl |
| Novo Nordisk INC | $60.37 | 2025 | Rivfloza |
| Abbvie INC. | $50.67 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $49.67 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $47.12 | 2024 | |
| Procept Biorobotics Corporation | $45.63 | 2024 | Aquabeam System |
| Myriad Genetic Laboratories, INC. | $42.07 | 2024 | Prolaris |
| Therapeuticsmd, INC. | $41.66 | 2019-2020 | |
| Smith+Nephew, INC. | $41.35 | 2020-2021 | |
| Tolmar Pharmaceuticals, INC. | $36.07 | 2020-2022 | |
| Medtronic, INC. | $34.74 | 2025 | Interstim |
| Olympus America INC. | $32.48 | 2023-2025 | Itind System |
| Janssen Biotech, INC. | $29.80 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $29.74 | 2023-2025 | Lynparza |
| Allergan, INC. | $29.43 | 2019 | |
| Tempus Ai, INC | $25.15 | 2024 | |
| Progenics Pharmaceuticals, INC. | $24.44 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $23.58 | 2023 | Seglentis |
| Neotract INC. | $22.60 | 2019 | |
| Merck Sharp & Dohme LLC | $20.60 | 2023 | Keytruda, Welireg, Lynparza |
| Covidien LP | $19.33 | 2019 | |
| Endo Pharmaceuticals INC. | $18.07 | 2023 | Aveed, Xiaflex |
| Rgh Enterprises LLC | $17.92 | 2020 | |
| Endo USA, INC. | $17.78 | 2025 | Aveed, Xiaflex |
| Blue Earth Diagnostics | $16.37 | 2019 | |
| Bioprotect Medical, INC. | $13.78 | 2025 | Bioprotect Balloon Implant System |
| Acell, INC. | $10.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Caire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.